GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

BioLASCO Taiwan Co 6662.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

28.00

-1.41%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About BioLASCO Taiwan Co

Its shares trade on Taipei Exchange under the ticker 6662.TWO. It has been listed since 4 January 2018. In the fiscal year to 31 December 2025, it reported revenue of TWD 262.7m and net income of TWD 42.4m. At that date it held total assets of TWD 592.6m and shareholders' equity of TWD 457.7m.

BioLASCO Taiwan Co., Ltd. engages in the production and sale of specific pathogen free experimental mice and rats including stocks inbreed strains, and immune deficient models. The company is headquartered in Taipei City, Taipei. The company went IPO on 2018-01-04. The firm also provides equipment related to feeding, supplies and testing platform, life science research and pharmaceutical development services.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Life Sciences Tools & Services
Listed since
4 Jan 2018

Leadership

Pay as last reported

  • Mr. Zhenzhong ChenChairman of the Board, since 2001
  • Mr. Yonghao ChenGeneral Manager
  • Mr. Ningyuan CaiDeputy General Manager-Biotechnology Division
  • Beck ChangHead of Finance & Accounting, Corporate Governance Officer
  • Meiyu YouCorporate Governance Officer
  • Mr. Junwei ChenDirector
  • Mr. Weiming LiuDirector
  • Mr. Ming-Chieh ChenIndependent Director
  • Chin Ting WangIndependent Director
  • Mr. Fengji ZhengIndependent Director
  • Mr. Hanxin ZhengIndependent Director
  • Joe ChenIR Contact Officer, since 2025

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • BioLASCO Taiwan produces specific pathogen free experimental mice and rats for research.
  • The company offers immune deficient models to support advanced life science studies.
  • BioLASCO Taiwan provides equipment related to feeding and supplies for laboratories.

Weaknesses

  • The firm relies on specific pathogen free experimental mice and rats production.
  • BioLASCO Taiwan focuses on stocks inbreed strains rather than broader animal models.
  • The company provides testing platform services which may limit market diversification.

Opportunities

  • BioLASCO Taiwan can expand life science research services for global pharmaceutical clients.
  • The firm may grow by supplying immune deficient models to new markets.
  • BioLASCO Taiwan could increase sales of feeding equipment to international laboratories.

Threats

  • BioLASCO Taiwan faces competition in the specific pathogen free experimental mice market.
  • The firm risks losing clients if immune deficient models become obsolete.
  • BioLASCO Taiwan may struggle if testing platform demand decreases significantly.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.